favicon
  • Home
  • Our Research
    • Pipeline to Precision Medicine
    • LKB1 Tumour Suppressor kinase
    • Cytoskeleton
    • Neurodegenerative Diseases
    • Single-Cell Genomic Analysis
    • Funding Resources
  • Team
    • Dr. Paola Marignani
    • Current
    • Alumni
  • Publications
  • Facilities
    • Scientific Links
  • News
  • Contact
✕
  • Home
  • Our Research
    • Pipeline to Precision Medicine
    • LKB1 Tumour Suppressor kinase
    • Cytoskeleton
    • Neurodegenerative Diseases
    • Single-Cell Genomic Analysis
    • Funding Resources
  • Team
    • Dr. Paola Marignani
    • Current
    • Alumni
  • Publications
  • Facilities
    • Scientific Links
  • News
  • Contact
Dalhousie researchers find drug combination that ‘shut down’ tumours
January 2, 2015
Marignani on CTV Canada AM, on cancer and chemicals study
June 23, 2015
Dalhousie researchers find drug combination that ‘shut down’ tumours
January 2, 2015
Marignani on CTV Canada AM, on cancer and chemicals study
June 23, 2015
January 14, 2015

We speak with Dalhousie cancer researcher Dr. Paola Marignani about a new drug combination that can be used to shut down tumors.

See the original article at https://halifax.citynews.ca/2015/01/14/the-sheldon-macleod-show-2-pm-48/

Share
cropped-favicon.png
  • Home
  • Single-Cell Genomic Analysis
  • Pipeline to Precision Medicine
  • Neurodegenerative Diseases
  • LKB1 Tumour Suppressor kinase
  • Cytoskeleton
  • Scientific Links
  • Funding Resources
  • Dr. Paola Marignani
  • Current Lab Members
  • Lab Alumni
  • Publications
  • In the News
  • Contact

 

 

Dalhousie University sits on Mi’kma’ki, the ancestral and unceded territory of the Mi’kmaq People. We are all Treaty People. We recognize that African Nova Scotians are a distinct people whose histories, legacies and contributions have enriched that part of Mi’kma’ki known as Nova Scotia for over 400 years.

Pipeline to precision health.
Based in Halifax, Nova Scotia.
© 2025 Marignani Discovery Research Laboratory. All Rights Reserved.